-
1
-
-
84890935712
-
US Renal Data System 2013 Annual Data Report
-
Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, et al: US Renal Data System 2013 Annual Data Report. Am J Kidney Dis 2014; 63:A7.
-
(2014)
Am J Kidney Dis
, vol.63
, pp. A7
-
-
Collins, A.J.1
Foley, R.N.2
Chavers, B.3
Gilbertson, D.4
Herzog, C.5
-
2
-
-
84896720713
-
Microalbuminuria as a risk predictor in diabetes: The continuing saga
-
Bakris GL, Molitch M: Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 2014; 37: 867-875.
-
(2014)
Diabetes Care
, vol.37
, pp. 867-875
-
-
Bakris, G.L.1
Molitch, M.2
-
3
-
-
33646771273
-
Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective
-
Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69: 2057-2063.
-
(2006)
Kidney Int
, vol.69
, pp. 2057-2063
-
-
Parving, H.H.1
Lewis, J.B.2
Ravid, M.3
Remuzzi, G.4
Hunsicker, L.G.5
-
4
-
-
77649217358
-
Albuminuria in non-primary renal disease: Risk marker rather than risk factor
-
de Jong PE, Gansevoort RT: Albuminuria in non-primary renal disease: risk marker rather than risk factor. Nephrol Dial Transplant 2010; 25: 656-658.
-
(2010)
Nephrol Dial Transplant
, vol.25
, pp. 656-658
-
-
De Jong, P.E.1
Gansevoort, R.T.2
-
5
-
-
79960132102
-
Changes in albuminuria predict mortality and morbidity in patients with vascular disease
-
Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, et al: Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353-1364.
-
(2011)
J Am Soc Nephrol
, vol.22
, pp. 1353-1364
-
-
Schmieder, R.E.1
Mann, J.F.2
Schumacher, H.3
Gao, P.4
Mancia, G.5
-
6
-
-
2442680120
-
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
-
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
-
(2004)
Kidney Int
, vol.65
, pp. 2309-2320
-
-
De Zeeuw, D.1
Remuzzi, G.2
Parving, H.H.3
Keane, W.F.4
Zhang, Z.5
-
7
-
-
84926610786
-
Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: An analysis of the ONTARGET and TRANSCEND studies
-
Schmieder RE, Schutte R, Schumacher H, Bohm M, Mancia G, et al: Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. Diabetologia 2014; 57: 2019-2029.
-
(2014)
Diabetologia
, vol.57
, pp. 2019-2029
-
-
Schmieder, R.E.1
Schutte, R.2
Schumacher, H.3
Bohm, M.4
Mancia, G.5
-
8
-
-
84892649479
-
Standards of medical care in diabetes-2014
-
American Diabetes Association
-
American Diabetes Association: Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(suppl 1):S14-S80.
-
(2014)
Diabetes Care
, vol.37
, pp. S14-S80
-
-
-
9
-
-
80052689989
-
Renal protection with angiotensin receptor blockers: Where do we stand
-
Schmieder RE, Ruilope LM, Barnett AH: Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol 2011; 24: 569-580.
-
(2011)
J Nephrol
, vol.24
, pp. 569-580
-
-
Schmieder, R.E.1
Ruilope, L.M.2
Barnett, A.H.3
-
10
-
-
70349277003
-
Effects of angiotensin II receptor blockers on diabetic nephropathy
-
Kalaitzidis R, Bakris GL: Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens Suppl 2009; 27:S15-S21.
-
(2009)
J Hypertens
, vol.27
, pp. S15-S21
-
-
Kalaitzidis, R.1
Bakris, G.L.2
-
11
-
-
84905773019
-
Executive summary: Standards of medical care in diabetes-2014
-
American Diabetes Association
-
American Diabetes Association: Executive summary: standards of medical care in diabetes-2014. Diabetes Care 2014; 37 (suppl 1):S5-S13.
-
(2014)
Diabetes Care
, vol.37
, pp. S5-S13
-
-
-
12
-
-
0037005819
-
Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure
-
Tang WH, Vagelos RH, Yee YG, Benedict CR, Willson K, et al: Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39: 70-78.
-
(2002)
J Am Coll Cardiol
, vol.39
, pp. 70-78
-
-
Tang, W.H.1
Vagelos, R.H.2
Yee, Y.G.3
Benedict, C.R.4
Willson, K.5
-
13
-
-
0019865836
-
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
-
Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91: 457-465.
-
(1981)
J Endocrinol
, vol.91
, pp. 457-465
-
-
Staessen, J.1
Lijnen, P.2
Fagard, R.3
Verschueren, L.J.4
Amery, A.5
-
14
-
-
34548163060
-
The incidence and implications of aldosterone breakthrough
-
Bomback AS, Klemmer PJ: The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492.
-
(2007)
Nat Clin Pract Nephrol
, vol.3
, pp. 486-492
-
-
Bomback, A.S.1
Klemmer, P.J.2
-
15
-
-
12144252958
-
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate
-
Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH: Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939.
-
(2004)
Diabetologia
, vol.47
, pp. 1936-1939
-
-
Schjoedt, K.J.1
Andersen, S.2
Rossing, P.3
Tarnow, L.4
Parving, H.H.5
-
16
-
-
33749128531
-
Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy
-
Horita Y, Taura K, Taguchi T, Furusu A, Kohno S: Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton) 2006; 11: 462-466.
-
(2006)
Nephrology (Carlton)
, vol.11
, pp. 462-466
-
-
Horita, Y.1
Taura, K.2
Taguchi, T.3
Furusu, A.4
Kohno, S.5
-
18
-
-
38149030811
-
Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review
-
Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ: Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
-
(2008)
Am J Kidney Dis
, vol.51
, pp. 199-211
-
-
Bomback, A.S.1
Kshirsagar, A.V.2
Amamoo, M.A.3
Klemmer, P.J.4
-
19
-
-
0035922443
-
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease
-
Chrysostomou A, Becker G: Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926.
-
(2001)
N Engl J Med
, vol.345
, pp. 925-926
-
-
Chrysostomou, A.1
Becker, G.2
-
20
-
-
24144495285
-
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study
-
Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112.
-
(2005)
Diabetes Care
, vol.28
, pp. 2106-2112
-
-
Rossing, K.1
Schjoedt, K.J.2
Smidt, U.M.3
Boomsma, F.4
Parving, H.H.5
-
21
-
-
0037222490
-
Effectiveness of aldosterone blockade in patients with diabetic nephropathy
-
Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
-
(2003)
Hypertension
, vol.41
, pp. 64-68
-
-
Sato, A.1
Hayashi, K.2
Naruse, M.3
Saruta, T.4
-
22
-
-
33750331264
-
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
-
Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, et al: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
-
(2006)
Clin J Am Soc Nephrol
, vol.1
, pp. 940-951
-
-
Epstein, M.1
Williams, G.H.2
Weinberger, M.3
Lewin, A.4
Krause, S.5
-
23
-
-
84864493727
-
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
-
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, et al: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847.
-
(2012)
Eur Heart J
, vol.33
, pp. 1787-1847
-
-
McMurray, J.J.1
Adamopoulos, S.2
Anker, S.D.3
Auricchio, A.4
Bohm, M.5
-
24
-
-
0033517302
-
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
-
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
-
(1999)
N Engl J Med
, vol.341
, pp. 709-717
-
-
Pitt, B.1
Zannad, F.2
Remme, W.J.3
Cody, R.4
Castaigne, A.5
-
25
-
-
78650399880
-
Eplerenone in patients with systolic heart failure and mild symptoms
-
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, et al: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
-
(2011)
N Engl J Med
, vol.364
, pp. 11-21
-
-
Zannad, F.1
McMurray, J.J.2
Krum, H.3
Van Veldhuisen, D.J.4
Swedberg, K.5
-
26
-
-
84861554853
-
Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases
-
Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, et al: Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012; 7: 1385-1403.
-
(2012)
ChemMedChem
, vol.7
, pp. 1385-1403
-
-
Bärfacker, L.1
Kuhl, A.2
Hillisch, A.3
Grosser, R.4
Figueroa-Perez, S.5
-
27
-
-
84904267679
-
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury
-
Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, et al: Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014; 64: 69-78.
-
(2014)
J Cardiovasc Pharmacol
, vol.64
, pp. 69-78
-
-
Kolkhof, P.1
Delbeck, M.2
Kretschmer, A.3
Steinke, W.4
Hartmann, E.5
-
28
-
-
84882415231
-
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial
-
Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, et al: Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013; 34: 2453-2463.
-
(2013)
Eur Heart J
, vol.34
, pp. 2453-2463
-
-
Pitt, B.1
Kober, L.2
Ponikowski, P.3
Gheorghiade, M.4
Filippatos, G.5
-
29
-
-
84869492851
-
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
-
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, et al: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213.
-
(2012)
N Engl J Med
, vol.367
, pp. 2204-2213
-
-
Parving, H.H.1
Brenner, B.M.2
McMurray, J.J.3
De Zeeuw, D.4
Haffner, S.M.5
-
30
-
-
70949108082
-
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
-
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
-
(2009)
N Engl J Med
, vol.361
, pp. 2019-2032
-
-
Pfeffer, M.A.1
Burdmann, E.A.2
Chen, C.Y.3
Cooper, M.E.4
De Zeeuw, D.5
-
31
-
-
84890946148
-
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease
-
de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, et al: Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369: 2492-2503.
-
(2013)
N Engl J Med
, vol.369
, pp. 2492-2503
-
-
De Zeeuw, D.1
Akizawa, T.2
Audhya, P.3
Bakris, G.L.4
Chin, M.5
-
32
-
-
0037417252
-
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
-
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, et al: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
-
(2003)
N Engl J Med
, vol.348
, pp. 1309-1321
-
-
Pitt, B.1
Remme, W.2
Zannad, F.3
Neaton, J.4
Martinez, F.5
-
33
-
-
84859176250
-
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee
-
Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, et al: Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J Card Fail 2012; 18: 265-281.
-
(2012)
J Card Fail
, vol.18
, pp. 265-281
-
-
Butler, J.1
Ezekowitz, J.A.2
Collins, S.P.3
Givertz, M.M.4
Teerlink, J.R.5
-
34
-
-
84884294190
-
2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines
-
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, et al: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147-e239.
-
(2013)
J Am Coll Cardiol
, vol.62
, pp. e147-e239
-
-
Yancy, C.W.1
Jessup, M.2
Bozkurt, B.3
Butler, J.4
-
35
-
-
77955926343
-
Aldosterone blockade in chronic kidney disease: Can it improve outcome
-
Toto RD: Aldosterone blockade in chronic kidney disease: can it improve outcome? Curr Opin Nephrol Hypertens 2010; 19: 444-449.
-
(2010)
Curr Opin Nephrol Hypertens
, vol.19
, pp. 444-449
-
-
Toto, R.D.1
-
36
-
-
84861563400
-
Rationale and design of ARTS: A randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
-
Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, et al: Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 2012; 14: 668-675.
-
(2012)
Eur J Heart Fail
, vol.14
, pp. 668-675
-
-
Pitt, B.1
Filippatos, G.2
Gheorghiade, M.3
Kober, L.4
Krum, H.5
-
37
-
-
84890067870
-
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: The Occurrence of renal eveNts (BEACON) trial
-
Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, et al: Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant 2013; 28: 2841-2850.
-
(2013)
Nephrol Dial Transplant
, vol.28
, pp. 2841-2850
-
-
Lambers Heerspink, H.J.1
Chertow, G.M.2
Akizawa, T.3
Audhya, P.4
Bakris, G.L.5
-
38
-
-
84865642129
-
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)
-
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, et al: Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13: 387-393.
-
(2012)
J Renin Angiotensin Aldosterone Syst
, vol.13
, pp. 387-393
-
-
Parving, H.H.1
Brenner, B.M.2
McMurray, J.J.3
De Zeeuw, D.4
Haffner, S.M.5
-
39
-
-
77956644609
-
The RAAS in the pathogenesis and treatment of diabetic nephropathy
-
Ruggenenti P, Cravedi P, Remuzzi G: The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010; 6: 319-330.
-
(2010)
Nat Rev Nephrol
, vol.6
, pp. 319-330
-
-
Ruggenenti, P.1
Cravedi, P.2
Remuzzi, G.3
|